OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740.
Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. OT3-01-03: Pre-Surgical Evaluation of the AKT Inhibitor MK-2206 in Patients with Operable Invasive Breast Cancer: New York Cancer Consortium Trial P8740. Cancer Research 2011, 71: ot3-01-03-ot3-01-03. DOI: 10.1158/0008-5472.sabcs11-ot3-01-03.Peer-Reviewed Original ResearchPre-surgical studyInvasive breast cancerBreast cancerPI3K/AktWeekly MKPost-treatment tissue samplesOperable invasive breast cancerPeripheral blood mononuclear cellsEarly phase clinical studiesDownstream PI3K/Akt pathwayClinical stage IClinical trial programBlood mononuclear cellsMain eligibility criteriaPre-surgical evaluationEarly clinical testingPI3K/Akt pathwayEffects of MKAKT inhibitor MKPost-treatment samplesAnti-cancer propertiesParaffin-embedded tissuesAccrue patientsAnti-cancer agentsNeoadjuvant chemotherapyPresurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. Journal Of Clinical Oncology 2011, 29: tps147-tps147. DOI: 10.1200/jco.2011.29.15_suppl.tps147.Peer-Reviewed Original ResearchOperable invasive breast cancerInvasive breast cancerAKT inhibitor MKPresurgical evaluationBreast cancerInhibitor MKPatientsCancer